Bracco VueJect FDA and Health Canada Clearance
Analysis based on 11 articles · First reported Aug 11, 2026 · Last updated Aug 11, 2026
The regulatory clearances enable Bracco S.p.A. — Bracco Imaging to commercialize VueJect in the U.S. and Canadian markets, potentially strengthening its position in the contrast-enhanced ultrasound segment and driving revenue growth. The approvals may also enhance Bracco's competitive standing against other diagnostic imaging companies, though the immediate financial impact is likely modest given the niche nature of the product.
Bracco S.p.A. — Bracco Imaging announced on August 11, 2026, that its VueJect ultrasound contrast delivery system received 510(k) clearance from the U.S. United States — Food and Drug Administration and authorization from Canada — Health Canada. VueJect is the first dedicated ultrasound contrast delivery system engineered for cardiology imaging, designed to standardize and improve the efficiency of contrast administration in echocardiography procedures. The approvals mark the first step in Bracco's global commercialization strategy, with initial availability in the United States and Canada and plans for additional regulatory submissions in other markets. The system is intended to reduce operator variability and enable continuous administration of ultrasound contrast agents, supporting more consistent enhancement during cardiac imaging. Bracco executives, including CEO Fulvio Renoldi Bracco, highlighted the strategic importance of the milestone in advancing contrast-enhanced ultrasound worldwide.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard